Short Interest in Dogwood Therapeutics, Inc (NASDAQ:DWTX) Expands By 40.9%

Dogwood Therapeutics, Inc (NASDAQ:DWTX) was the target of a significant increase in short interest during the month of March. As of March 31st, there was short interest totaling 70,605 shares, an increase of 40.9% from the March 15th total of 50,105 shares. Based on an average trading volume of 99,784 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.2% of the company’s stock are sold short.

Dogwood Therapeutics Stock Performance

Shares of NASDAQ DWTX opened at $1.56 on Friday. Dogwood Therapeutics has a 1 year low of $1.54 and a 1 year high of $9.50. The firm has a market cap of $52.10 million, a price-to-earnings ratio of -0.08 and a beta of 2.05. The stock’s 50-day simple moving average is $2.61 and its 200-day simple moving average is $4.28.

Dogwood Therapeutics (NASDAQ:DWTX) last announced its earnings results on Wednesday, March 18th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.96. As a group, research analysts predict that Dogwood Therapeutics will post -6.43 EPS for the current year.

Institutional Trading of Dogwood Therapeutics

A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP acquired a new stake in Dogwood Therapeutics, Inc (NASDAQ:DWTX) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned about 0.51% of Dogwood Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 9.05% of the company’s stock.

Analysts Set New Price Targets

DWTX has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Dogwood Therapeutics in a research report on Friday, February 20th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dogwood Therapeutics in a research report on Monday, December 22nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Dogwood Therapeutics currently has a consensus rating of “Hold” and an average price target of $12.00.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.